SPOTLIGHT: BMS, Exelixis extend pact


Exelixis and Bristol-Myers Squibb have extended their pact to develop and commercialize therapies targeted against the Liver X Receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.